N. Kothari

Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.

M. Motyl, J. Karlowsky, D. Sahm, 2019, The Journal of antimicrobial chemotherapy.

In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017.

M. Motyl, J. Karlowsky, D. Sahm, 2020, Journal of medical microbiology.

1359. Activity of Meropenem/Nacubactam Combination Against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017

I. Morrissey, F. García-Alcalde, A. Haldimann, 2018, Open Forum Infectious Diseases.

In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates.

J. Karlowsky, K. Hamed, S. Hawser, 2019, Diagnostic microbiology and infectious disease.

P476 Monitoring antifungal resistance in a global collection of Candida spp. surveillance isolates, including C. auris—analysis of resistance in antifungals (ARIA) 2020 study

S. Hawser, T. Mathur, N. Kothari, 2022, Medical Mycology.

Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam.

I. Morrissey, P. Knechtle, S. Hawser, 2021, Journal of global antimicrobial resistance.

Susceptibility of Ceftobiprole against Gram-positive and Gram-negative Clinical Isolates from 2019 from different European territories.

S. Hawser, Nowel Redder, Noelle Jemmely, 2022, Journal of global antimicrobial resistance.

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

P. Savoia, S. Hawser, L. Ferrari, 2022, Antibiotics.